"GSK pumps up to $800m for US manufacturing site upgrade" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been ...

The site is slated to help produce freeze-dried vaccines such as the company's respiratory syncytial virus launch Arexvy and its shingles vaccine Shingrix. GSK pumps £200M+ into UK manufacturing ...

GSK expects to begin construction immediately on the project, which includes a new 270,000-square-foot-facility for research and manufacturing ... produced at other sites and employs 380 people.

Additionally, GSK will establish a new vaccines drug substance facility at the site, dedicated to manufacturing products based on the company’s novel MAPS technology, subsequent to future ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster ...

According to GSK, this new investment will be utilized to bring state-of-the-art drug substance manufacturing and additional ... underway at the Marietta site.” Moving forward, construction ...

GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...

Following outlays for sites in the UK and Belgium earlier this year, GSK is planning to invest up to $800m in the US to double the size and capacity of its site in Marietta, Pennsylvania.